Related Experiment Video
Updated: Oct 2, 2026
Tuina Intervention in Rabbit Model of Knee Osteoarthritis
Published on: August 25, 2023
Experience with a placebo-controlled randomized clinical trial of a disease-modifying drug for osteoarthritis: the
Kenneth D Brandt1, Steven A Mazzuca
1Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202-5100, USA. kbrandt@iupui.edu
Abstract:
Little effort has gone into the development of more effective analgesics for osteoarthritic pain. Efforts to improve symptomatic therapy for osteoarthritis have been deflected or diluted by a decision to pursue the development of disease-modifying OA drugs (DMOADs). These agents' main mechanism of action is directed not at the relief of joint pain but at slowing the progression of structural damage. This article describes the results of a recent randomized placebo-controlled designed to examine the DMOAD effect in humans of the tetracycline antibiotic doxycycline, and reviews the experience gained from other recent DMOAD trials in humans.
Insights
Developing effective osteoarthritis pain relief has lagged. This study examined doxycycline as a disease-modifying osteoarthritis drug (DMOAD), finding limited symptomatic benefit for joint pain.
Area of Science:
- Rheumatology
- Pharmacology
- Biomedical Engineering
Background:
- Osteoarthritis (OA) pain management remains a significant clinical challenge.
- Current research focus has shifted towards disease-modifying osteoarthritis drugs (DMOADs) over symptomatic analgesics.
- DMOADs aim to slow structural joint damage rather than directly alleviate pain.
Purpose of the Study:
- To evaluate the disease-modifying osteoarthritis drug (DMOAD) potential of doxycycline in human subjects.
- To assess the efficacy of doxycycline in managing osteoarthritic pain.
- To review outcomes from recent human DMOAD trials.
Main Methods:
- A randomized, placebo-controlled trial was conducted.
- The study investigated the effects of the tetracycline antibiotic, doxycycline.
- Human participants with osteoarthritis were included.
Main Results:
- Doxycycline demonstrated limited symptomatic relief for osteoarthritic joint pain.
- The study provides insights into the challenges of developing effective DMOADs.
- Review of other DMOAD trials highlighted similar findings regarding symptomatic efficacy.
Conclusions:
- Current DMOAD development strategies may not adequately address the immediate need for effective osteoarthritis pain relief.
- Further research is needed to develop analgesics that target osteoarthritic pain effectively.
- Doxycycline's role as a DMOAD for symptomatic OA pain requires further investigation.
More Related Videos
04:50Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
Published on: May 16, 2025
07:19Clinical Efficacy of Tissue-Bone Homeostasis Manipulation on Soft Tissue Balance and Function in Knee Osteoarthritis
Published on: June 16, 2026